15.07.2024 13:35:10
|
Lupin Divests U.S. Commercial Women's Health Specialty Business To Evofem Biosciences
(RTTNews) - Pharma major Lupin Ltd. announced Monday that it has divested its U.S. Commercial Women's Health Specialty Business to Evofem Biosciences, Inc. (EVFM), a U.S. biopharmaceutical company focused exclusively on Women's Health.
Lupin's U.S. Commercial Women's Health Specialty Business is primarily focused on commercializing SOLOSEC (secnidazole) 2g oral granules.
This FDA-approved single-dose antimicrobial agent provides a complete course of therapy for the treatment of bacterial vaginosis (BV) and trichomoniasis, two common sexual health infections.
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Evofem Biosciences Incmehr Nachrichten
Keine Nachrichten verfügbar. |